INTRODUCTION {#s1}
============

Cervical carcinoma is one of the most commonly occurring cancers in women worldwide \[[@R1], [@R2]\], while greater than 99% of the disease contains human papillomavirus (HPV) sequences \[[@R3], [@R4]\]. Viral oncoproteins E6 and E7 encoded by HPV, which would respectively inactivate p53 and members of the pRb family, interfere with the cellular control mechanisms of the cell cycle. In addition, some studies demonstrated that these two oncoproteins also cooperatively disturb the mechanisms of chromosome duplication and segregation during mitosis and induce thereby severe chromosomal instability \[[@R5]\].

Studies have shown a significant correlation between integration and progression of cervical dysplastic lesions to invasive carcinomas. In pre-invasive lesions, HPV16 integration has already been found to occur in cervical intraepithelial neoplasia (CIN) \[[@R6]\], whereas in most cases of invasive carcinoma, HPV DNA sequences are frequently integrated into the host genome \[[@R7]--[@R10]\]. Although not much is known about the exact mechanisms of HPV genome integration, it is widely accepted that HPV integration can be a driver mutation in cervical carcinogenesis, with consequences influencing both the cellular and viral genomes. Recently, Akagi et al. presented a model of "looping" by which HPV integrant-mediated DNA replication and recombination may result in viral-host DNA concatemers, disrupting genes involved in oncogenesis and/or amplifying HPV oncogenes E6 and E7. Their results suggested that HPV directly promotes genomic instability \[[@R11]\]. Therefore, viral genome integration represents a crucial step in tumorigenesis, and elucidation of these particular integration events is pertinent for understanding HPV induced carcinogenesis.

Determining the DNA sequence of viral-cellular junctions would therefore indicate most directly HPV integration, as attempted in a number of previous studies where genomic HPV integration sites had been analyzed via many different assays. However, the precise identification of tiny stretches against a background of massive amount of episomal forms is an ongoing technical challenge. In addition, due to the nature of integration, which may be incorporated either as a single or multiple numbers of concatenated form, the latter can actually hinder integration detection \[[@R12]\]. Thus, development of more efficient methods would facilitate a comprehensive mapping of HPV integration sites to gain deeper insight into cervical carcinogenesis.

Here, in order to contribute to the understanding of the presence and the precise localization of HPV integration sites in cervical cancer, we studied a large series of cases using base-resolution genome-wide HPV capture technology with the next generation sequencing. More specifically, we simultaneously evaluate HPV prevalence and detailed characterization of the exact integration sites of the HPV DNA into the human genome in 47 primary cervical cancer samples and 2 cell lines.

RESULTS {#s2}
=======

In this study, 49 DNA samples including 47 from fresh-frozen cervical carcinomas and 2 cervical cancer cell lines (SiHa and HeLa) were detected using the method of HPV capture combined with next generation sequencing ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}).

Distribution of HPV subtypes {#s2_1}
----------------------------

All the DNA samples were captured with a total of 17 HPV types (6, 11, 16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59, 66, 68, 69, and 82). Of the 47 cancer samples, we were able to capture HPV DNA in 39 samples. Of these 39 samples, 30 were positive for HPV16. In addition to HPV 16, we also detected HPV18 (*n* = 4), 58 (*n* = 5), 45 (*n* = 1), 31 (*n* = 1). Two samples in this analysis harbored both types of HPV, HPV16 and HPV18 in T35, HPV18 and HPV58 in T9, respectively. However, in T35, the sequencing depth of HPV16 is 34-fold greater than that of HPV18, and in T9, the sequencing depth of HPV18 is 13 fold greater than that of HPV58. Therefore, only HPV16 in T35 and HPV18 in T9 were analyzed in subsequent HPV assay. SiHa was positive for HPV16, and HeLa was positive for HPV18 ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}).

Determination of potential HPV integration sites {#s2_2}
------------------------------------------------

As described in the Bioinformatics Analysis method, if a specific position has one or more discordant read pairs mapped with one end to a human chromosome and the other to the HPV reference genome, it will be considered as a potential HPV integration site. A total of 319 potential HPV integration sites were discovered in 25 HPV DNA-positive cases including 19 cases for HPV16, 3 cases for HPV18, 1 cases for HPV58, and 2 cell lines (SiHa, HeLa), with frequencies ranging from 1 to 59 per sample ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). The prevalence of integrated HPV16 DNA was 63% (19/30), while the prevalence of integrated HPV18 DNA reached 100% (3/3). Additionally, HPV integration was detected in one HPV58 DNA-positive sample, but the HPV45 and HPV31-positive cases showed no integration (Figure [1](#F1){ref-type="fig"} and [Supplementary Table S1](#SD1){ref-type="supplementary-material"}).

![The distribution of HPV subtypes in 47 cervical cancer cases\
Red indicates samples with integration sites, and gray indicates samples with no integration.](oncotarget-07-5852-g001){#F1}

Validation and assay of HPV integration sites {#s2_3}
---------------------------------------------

In the attempt to confirm the newly uncovered HPV integration sites and further identify the exact integration site and the sequence between viral and cellular genome, all the 319 potential HPV integration sites were detected via targeted PCR amplification and Sanger sequencing. The Sanger sequencing validation rate based on one, two, three, or more than three discordant paired-end reads, was 3.7% (6/162), 47.8% (22/46), 44.4% (4/9), and 83.3% (85/102), respectively ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). The sequences of the fusion genes were first characterized by the NCBI human mega Blast database alignment tool and the UCSC Blat database to obtain the nucleotide resolution of the gene. A total of 117 unique HPV integration sites were identified, including HPV16 (*n* = 101), HPV18 (*n* = 7), and HPV58 (*n* = 9) (Table [1](#T1){ref-type="table"} and [Supplementary Tables S1](#SD1){ref-type="supplementary-material"} and [S2](#SD1){ref-type="supplementary-material"}); thus providing further basis upon which to perform additional research on these validated integration sites.

###### HPV-cellular DNA junctions confirmed by PCR amplification and Sanger sequencing

  Sample name   \#reads   HPV                    Cellular sequence   
  ------------- --------- ------- -------------- ------------------- ----------
  T4            4         HPV16   2046 (E1)      54417043            19q13.42
  T4            5         HPV16   5190 (L2)      54417038            19q13.42
  T8            2         HPV16   704 (E7)       59171259            17q23.2
  T15           9         HPV16   3781 (E2)      73996849            13q22.1
  T16           70        HPV16   2849 (E2)      17799430            7p21.1
  T17           19        HPV16   2600 (E1)      53765119            19q13.42
  T17           4         HPV16   3575 (E2/E4)   240309623           2q37.3
  T17           1         HPV16   4448 (L2)      240281037           2q37.3
  T18           78        HPV16   1063 (E1)      74594785            4q13.3
  T20           831       HPV16   2689 (E1)      123715736           10q26.13
  T20           400       HPV16   2863 (E2)      1019766             10p15.3
  T23           8         HPV16   850 (E7)       32515477            20q11.22
  T23           5         HPV16   884 (E1)       32487936            20q11.22
  T23           14        HPV16   1277 (E1)      50054               18p11.32
  T23           46        HPV16   2623 (E1)      8814272             6p24.3
  T23           8         HPV16   2724 (E1)      30948621            20q11.21
  T23           940       HPV16   2804 (E1/E2)   32516985            20q11.22
  T23           12        HPV16   2891 (E2)      12645768            6p24.1
  T23           21        HPV16   3163 (E2)      20462931            xp22.12
  T23           8         HPV16   3182 (E2)      32516400            20q11.22
  T23           131       HPV16   3328 (E2)      7328094             6p24.3
  T23           43        HPV16   3344 (E2/E4)   7327990             6p24.3
  T23           4         HPV16   3883 (E5)      156990726           3q25.31
  T23           2         HPV16   4393 (L2)      17224129            12p12.3
  T23           2         HPV16   4405 (L2)      99438640            2q11.2
  T23           4         HPV16   4453 (L2)      32472391            20q11.22
  T23           22        HPV16   4681 (L2)      7326060             6p24.3
  T23           43        HPV16   5535 (L2)      20464412            xp22.12
  T23           2         HPV16   5745 (L1)      103893590           11q22.3
  T23           12        HPV16   6618 (L1)      32506420            20q11.22
  T25           5         HPV16   1161 (E1)      31689429            10p11.22
  T32           23        HPV16   3611 (E2/E4)   873456              9p24.3
  T33           8         HPV16   958 (E1)       107223556           7q22.3
  T33           4         HPV16   1558 (E1)      99425642            15q26.3
  T33           2         HPV16   2744 (E1)      67500034            13q21.32
  T33           8         HPV16   4911 (L2)      10702626            21p11.2
  T34           5         HPV16   7 (LCR)        9283840             11p15.4
  T34           2         HPV16   38 (LCR)       126566946           Xq25
  T34           2         HPV16   1043 (E1)      9292546             11p15.4
  T34           2         HPV16   1079 (E1)      128770421           8q24.21
  T34           35        HPV16   1099 (E1)      128840275           8q24.21
  T34           2         HPV16   1844 (E1)      25871313            5p14.1
  T34           9         HPV16   2104 (E1)      128717682           8q24.21
  T34           6         HPV16   2672 (E1)      64430179            4q13.1
  T34           5         HPV16   2810 (E1/E2)   128578637           8q24.21
  T34           4         HPV16   3355 (E2/E4)   126566939           xq25
  T34           11        HPV16   3644 (E2)      128596370           8q24.21
  T34           5         HPV16   3742 (E2)      9697576             11p15.4
  T34           2         HPV16   5599 (L2/L1)   25871329            5p14.1
  T34           3         HPV16   5629 (L2/L1)   128827759           8q24.21
  T34           2         HPV16   5761 (L1)      9331203             11p15.4
  T34           1         HPV16   7877 (LCR)     128579990           8q24.21
  T35           4         HPV16   379 (E6)       129056613           8q24.21
  T35           6         HPV16   738 (E7)       129040142           8q24.21
  T35           2         HPV16   1362 (E1)      1806549             4p16.3
  T35           3         HPV16   2941 (E2)      23578398            6p22.3
  T35           29        HPV16   4963 (L2)      59909510            2p16.1
  T35           107       HPV16   5609 (L2/L1)   154556784           7q36.2
  T35           3241      HPV16   5619 (L2/L1)   129019228           8q24.21
  T35           4         HPV16   7567 (LCR)     31618653            1p35.2
  T36           4         HPV16   164 (E6)       22388589            11p14.3
  T36           4         HPV16   2919 (E2)      85639302            2p11.2
  T36           2         HPV16   3717 (E2)      85639289            2p11.2
  T38           122       HPV16   384 (E6)       14288872            9p22.3
  T38           668       HPV16   551 (E6)       14275445            9p22.3
  T38           1         HPV16   858 (E7)       15070638            20p12.1
  T38           3         HPV16   1690 (E1)      14330266            9p22.3
  T38           1         HPV16   1975 (E1)      14869191            20p12.1
  T38           2         HPV16   1987 (E1)      14872325            20p12.1
  T38           5         HPV16   2508 (E1)      15079958            20p12.1
  T38           9         HPV16   3647 (E2)      14246496            9p22.3
  T38           3         HPV16   4652 (L2)      14388662            9p22.3
  T38           1         HPV16   7480 (LCR)     15074857            20p12.1
  T38           1394      HPV16   7708 (LCR)     14875592            20p12.1
  T38           5         HPV16   7856 (LCR)     14236572            9p22.3
  T39           19        HPV16   1661 (E1)      189584107           3q28
  T39           22        HPV16   5300 (L2)      189584098           3q28
  T42           1         HPV16   697 (E7)       163224769           1q23.3
  T42           2         HPV16   1356 (E1)      96471972            Xq21.33
  T42           4         HPV16   1728 (E1)      93013206            6q15
  T42           6         HPV16   1942 (E1)      150420961           xq28
  T42           151       HPV16   2059 (E1)      94561088            6q16.1
  T42           2         HPV16   2189 (E1)      147585823           7q35
  T42           4         HPV16   2370 (E1)      117973872           7q31.31
  T42           2         HPV16   2816 (E2)      103005957           1p21.1
  T42           499       HPV16   2991 (E2)      188223631           2q32.1
  T42           4         HPV16   3331 (E2)      31137921            5p13.3
  T42           2         HPV16   3402 (E2/E4)   42298926            2p21
  T42           7         HPV16   4279 (L2)      117974122           7q31.31
  T42           12        HPV16   4879 (L2)      231434760           2q37.1
  T42           13        HPV16   5045 (L2)      86378287            14q31.3
  T43           4         HPV16   777 (E7)       164142942           2q24.3
  T43           36        HPV16   975 (E1)       73868139            13q22.1
  T43           2         HPV16   3721 (E2)      45180348            2p21
  T43           30        HPV16   4411 (L2)      73869942            13q22.1
  T47           2         HPV16   340 (E6)       10902225            19p13.2
  T47           4         HPV16   3501 (E2/E4)   62731602            17q24.1
  T47           2         HPV16   3800 (E2)      31923670            6p21.33
  T47           158       HPV16   3817 (E2)      57846210            6p11.2
  SiHa          201       HPV16   3132 (E2)      74087562            13q22.1
  SiHa          86        HPV16   3384 (E2/E4)   73788866            13q22.1
  T9            294       HPV18   3782 (E2)      57925564            17q23.1
  T31           6         HPV18   2918 (E2)      2539287             16p13.3
  T44           45        HPV18   2233 (E1)      49741244            8q11.21
  HeLa          496       HPV18   2497 (E1)      128241548           8q24.21
  HeLa          702       HPV18   3100 (E2)      128233367           8q24.21
  HeLa          5447      HPV18   5736 (L1)      128230632           8q24.21
  HeLa          211       HPV18   7857 (LCR)     128234255           8q24.21
  T11           29        HPV58   135 (E6)       45758413            18q21.1
  T11           129       HPV58   661 (E7)       66426391            11q13.2
  T11           4         HPV58   1244 (E1)      53599605            20q13.2
  T11           14        HPV58   2164 (E1)      64506111            4q13.1
  T11           2         HPV58   2195 (E1)      53582110            20q13.2
  T11           59        HPV58   3791 (E2)      47684812            15q21.1
  T11           1259      HPV58   5989 (L1)      53590867            20q13.2
  T11           461       HPV58   6833 (L1)      53615729            20q13.2
  T11           127       HPV58   7341 (LCR)     64506104            4q13.1

nucleotide position of viral-cellular breakpoints on the HPV genome (Alignment to NC_001526.2 for HPV16, NC_001357.1 for HPV18, and D90400.1 for HPV58);

Cellular nucleotide position of viral-cellular breakpoints on the human genome (Alignment to Hg19 human reference genome)

Abbreviations: T, Tumor; ORF, Open Reading Frame

SiHa and HeLa are cell lines with defined integration sites, which provide an invaluable standard for validation of diagnostic assays ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"} and [Supplementary Figure S2](#SD1){ref-type="supplementary-material"}). Consistent with other studies, two integration sites were observed in SiHa cell line at loci 13q22.1 \[[@R11], [@R13], [@R14]\] and four integration sites were observed in concatenated form in HeLa cell line at loci 8q24.21 \[[@R14]--[@R17]\].

Mapping viral-cellular breakpoints to viral genome {#s2_4}
--------------------------------------------------

The 101 validated HPV16 integration sites in 20 samples including SiHa were shown to be broadly distributed across the whole genome with a unique distribution profile, including E6 (*n* = 5), E7 (*n* = 6), E1 (*n* = 31), E1/E2 (*n* = 2), E2 (*n* = 20), E2/E4 (*n* = 7), E5 (*n* = 1), L2 (*n* = 15), L2/L1 (*n* = 4), L1 (*n* = 3), and LCR (*n* = 7) (Table [1](#T1){ref-type="table"} and Figure [2A](#F2){ref-type="fig"}). Due to the different length of each fragment, direct comparisons of integration site frequency per se among the fragments is not feasible. From the distribution of points within the scatter plot (Figure [2A](#F2){ref-type="fig"}), the most common regions of integration are E2, E4, and E7, followed by E1, L2, and E6, and the sparsest are in LCR, E5, and L1.

![The distribution of validated integration breakpoints\
(**A**) 117 validated integration breakpoints, identified in 25 HPV-positive cases including cell lines of SiHa and HeLa, are shown according to position in HPV genome. 99 validated HPV16 integration breakpoints identified in 19 primary cervical cancer samples are shown in black, 2 HPV16 integration breakpoints in SiHa cell line in red, 3 HPV18 integration breakpoints in 3 primary cervical cancer samples in blue, 4 HPV18 integration breakpoints in HeLa cell line in green, and 9 HPV58 integration breakpoints in 1 primary cervical cancer sample in purple. (**B**) The frequencies of 99 validated integration sites in 19 HPV16-positive primary cervical cancer samples are shown, ranging from 1 to 19 per sample. See also Table [1](#T1){ref-type="table"} and [Supplementary Table S1](#SD1){ref-type="supplementary-material"}.](oncotarget-07-5852-g002){#F2}

Additionally, the frequencies of HPV16 integration sites ranged from 1 to 19 per sample (Figure [2B](#F2){ref-type="fig"}). That is, a single HPV integration site was found in 6 cases; 3 cases found two sites and 2 cases found three. Three additional cases found four sites each, and there was one case each with eight, twelve, fourteen, sixteen and nineteen sites (*n* = 99 sites) (Figure [2B](#F2){ref-type="fig"} and [Supplementary Table S1](#SD1){ref-type="supplementary-material"}). Altogether, 68% (13/19) of the HPV16 DNA-positive carcinomas were found to harbor more than one integration sites per sample.

While the 7 validated HPV18 integration sites in 4 samples including HeLa cell line were only mapped in the E1 (*n* = 2), E2 (*n* = 3), L1 (*n* = 1) and LCR (*n* = 1) region of HPV genome (Table [1](#T1){ref-type="table"} and Figure [2A](#F2){ref-type="fig"}), the frequency of integration was one per sample except four in HeLa cell line (Table [1](#T1){ref-type="table"} and Figure [2A](#F2){ref-type="fig"}).

9 validated HPV58 integration sites in one sample were mapped in the E6 (*n* = 1), E7 (*n* = 1), E1 (*n* = 3), E2 (*n* = 1), L1 (*n* = 2), and LCR (*n* = 1) (Table [1](#T1){ref-type="table"} and Figure [2A](#F2){ref-type="fig"}).

Mapping viral-cellular breakpoints to chromosomal bands {#s2_5}
-------------------------------------------------------

Consistent with previous reports, integration sites were found to be located on virtually all the chromosomes, except chromosomes 22 (Figure [3](#F3){ref-type="fig"}). Besides, it is evident that several integration sites are clustered in some chromosomal regions, such as within the cytogenetic bands 6p24.3 (1.5M), 8q24.21 (0.8M), 9p22.3 (0.15M), 11p15.4 (0.4M), 13q22.1 (0.3M), 20p12.1 (0.2M), 20q11.22 (0.05M), and 20q13.2 (0.04M). Genomic distances among different viral integration sites in a "cluster", defined by more than three unique HPV integration sites, spanned up to 1.5 Mb. We carefully analyzed the detailed characterization of these clusters, and divided them into three groups. In the first group, a cytogenetic band showed three or more HPV integration sites for each sample, and it is plausible that they are integrated in a concatenated array, consistent with the recently suggested looping model \[[@R11]\]. For example, HPV integrant clusters mapped to 6p24.3 in T23 (*n* = 4), 9p22.3 in T38 (*n* = 6), 11p15.4 in T34 (*n* = 4), 20p12.1 in T38 (*n* = 6), 20q11.22 in T23 (*n* = 6), and 20q13.2 in T11 (*n* = 4). In the second group, some integrant clusters arose from at least three individual cases, and they may represent authentic hot spots, such as 13q22.1 in SiHa (*n* = 2), T15 (*n* = 1), and T43 (*n* = 2). In the last group, the clusters showed both of the aforementioned properties, such as 8q24.21 in HeLa (*n* = 4), T34 (*n* = 7), and T35 (*n* = 3) (Figure [3](#F3){ref-type="fig"}).

![Chromosome localization of the 117 HPV integration sites in 25 cases\
The chromosomal reference of all viral-cellular breakpoints with respect to Giemsa-stained bands was taken from the UCSC database. 25 HPV-positive cases with integration sites are shown in unique color. HPV integration sites were mapped to almost all the human chromosomes, except chromosomes 22. HPV integration sites are clustered on chromosome 6p24.3, 8q24.21, 9p22.3, 11p15.4, 13q22.1, 20p12.1, 20q11.22, and 20q13.2.](oncotarget-07-5852-g003){#F3}

Characterization of genomic DNA sequences adjacent to HPV integration breakpoints {#s2_6}
---------------------------------------------------------------------------------

Through PCR amplification and Sanger sequencing, we obtained the viral-cellular junction sequences. There were three patterns of host-virus sequences after aligning to the reference viral genome and human genome (hg19), including overlapping, inserting some unaligned nucleotides, and direct ligation ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}). Overlapping, defined by nucleotides shared between viral and cellular sequence, was the most prevalent pattern accounting for 67% of the 117 validated viral-cellular sequences. Since some nucleotides between viral and cellular sequence were not aligned to a particular genomic sequence, we categorized them as the insertion of some unaligned nucleotides, which group amounts to approximately 27% of all 117 sequences. About 6% of the 117 viral-cellular sequences were present with direct ligation. Additionally, information of the cellular sequences was observed and collected with RepeatMasker. It was found that 51.3% of the 117 integration sites were distributed in repeating elements throughout the human genome ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}), consistent with the actual proportion (50%) of repetitive sequence in the human genome \[[@R18]\].

All integration loci were checked for the presence of fragile sites. Of the 117 integration loci identified, 69 (59%) were located in or close to a fragile site ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}): 20 (17%) within common or rare fragile sites and 49 (42%) up to 5 Mb adjacent to fragile sites. 48 (41%) integration sites were not associated with fragile sites.

Meanwhile, the genomic regions within 50 kb of the viral-cellular junctions were investigated. Approximately 47% (55/117) of the 117 confirmed HPV integration sites were located within cellular genes, and 54 cellular DNA breakpoints were located in introns and one breakpoint was located in exon ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}). Moreover, the following cellular genes occurred in at least two unique HPV integration sites, including CACNG7 (2), CAPG (2), HDAC4 (2), TP63 (2), CAGE1 (2), PVT1 (5), MACROD2 (6), and NFIB (6). The targeted genes are in the same orientation as the cellular sequence of viral-cellular junctions in 31 HPV integration sites, and in the opposite orientation in 24 HPV integration sites ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}).

Correlation between HPV status and clinical information {#s2_7}
-------------------------------------------------------

Among the 47 patients with cervical cancer, 17 patients had received chemotherapy and radiotherapy before surgery, and the remaining 30 patients had not been treated before surgery ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). The prevalence of HPV DNA in 17 patients with treatment and in 30 patients without treatment before surgery was 76.5% (13/17), and 86.7% (26/30), respectively. However, there was no statistically significant difference (76.5% vs 86.7%, *P* = 0.435). In consideration of HPV integration status, we found that in 13 HPV DNA-positive patients treated with radiotherapy and chemotherapy before surgery, HPV integrations were not detected in 10 patients, including 8 patients positive for HPV16 and 1 patient positive for HPV45 and 1 patient positive for HPV58. Altogether, in 17 patients with cervical cancer who had received radiotherapy and chemotherapy before surgery, 82.4% (14/17) showed HPV negative or no HPV integration sites ([Supplementary Table S3](#SD1){ref-type="supplementary-material"}). According to the frequency of HPV16 integration sites per sample, we found that all the 5 cervical cancer cases harboring more than four HPV16 integration sites had received diagnosis of clinical stage III carcinoma ([Supplementary Table S1](#SD1){ref-type="supplementary-material"} and Figure [4](#F4){ref-type="fig"}). No significant difference was found between HPV integration and age at diagnosis ([Supplementary Table S3](#SD1){ref-type="supplementary-material"}).

![The correlation of number of integrated sites with clinical stages in 19 HPV16-positive cervical cancer samples\
According to the frequency of HPV16 integration sites per sample, we divide them into two groups, one is more than four HPV16 integration sites, and the other is no more than four HPV16 integration sites (*x*-axis). The number of patients with clinical stages in two groups is shown (*y*-axis).](oncotarget-07-5852-g004){#F4}

DISCUSSION {#s3}
==========

Utilization of the PCR-based approach has prevailed in the existing attempts of detection of HPV integration sites in the human genome, such as Amplification of Papillomavirus Oncogene Transcripts (APOT) in discriminating HPV mRNAs derived from integrated and episomal viral genomes \[[@R19], [@R20]\], Restriction Site PCR (RS-PCR) \[[@R21], [@R22]\], Southern blot and Detection of Integrated Papillomavirus Sequences (DIPS) in detecting integrated HPV DNA regardless of its transcriptional status \[[@R15]\], and Real-time PCR, which can determine the physical status (integrated or episomal) of HPV estimated by calculating HPV E2:E6/E7 ratio by real-time PCR amplification of HPV E2 and E6/E7 \[[@R23]\]. However, all these assays usually are time-consuming and fall short of sensitivity, because of a battery of type-specific primers adopted and innate random distribution of HPV integration sites. Furthermore, sensitivity may be heavily influenced by a number of factors, such as the virus copy number, the physical status (episomal or integrated of HPV), and integrated form (in a single copy or in concatenated form) \[[@R12]\]. To overcome these and other potential limitations, HPV capture combined with next generation sequencing, which presents a more efficient method as described here, is not only able to detect the signals of multiple virus in a single run with high specificity and sensitivity, but has the ability to distinguish, from a diverse background of mainly episomal or concatenated forms, a discreet number of integrated forms, and further determinate the sequence between viral and cellular junctions.

HPV capture in this study was designed based on probes from full-length HPV genome of 17 types. Thus, the HPV subtypes and HPV DNA integration sites were simultaneously detected in 49 cervical cancer samples (47 primary tumors and 2 cell lines). Out of which 82.9% of the 47 cervical cancer cases was HPV DNA positive, including HPV16(63.8%), HPV18(8.5%), HPV58(10.6%), HPV45 (2.1%), and HPV31 (2.1%). These percentages are relatively well aligned with existing findings \[[@R24]--[@R26]\], that is, HPV16 is by far the most prevalent type responsible for more than 50% of all the cervical cancer cases worldwide, followed by HPV18 and HPV58 and other high-risk HPV types that are less prevalent.

The sensitivity of the HPV capture combined with sequencing can be estimated from the results obtained from the well characterized cervical carcinoma cell lines SiHa and HeLa. SiHa, a HPV16-positive cervical cell line, harbors only one HPV16 DNA copy per cell \[[@R27], [@R28]\]. Two validated HPV integration sites were found in SiHa cell line, as the same sites reported previously \[[@R10]--[@R12]\] ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"} and [Supplementary Table S2](#SD1){ref-type="supplementary-material"}). Four HPV18 integration sites were detected on the chromosomal band 8q24.21 in HeLa cell line ([Supplementary Figure S2](#SD1){ref-type="supplementary-material"} and [Supplementary Table S2](#SD1){ref-type="supplementary-material"}), which were consistent with previous studies \[[@R15], [@R16]\]. Thus, our analysis had achieved 100% sensitivity and specificity compared with previous reported sites for SiHa and HeLa \[[@R11], [@R15], [@R16]\].

With this strategy, 117 unique and validated HPV integration sites and high-quality nucleotide sequences of the viral-cellular junctions were obtained. Of the 30 HPV16 DNA-positive cervical cancer samples, 63% (19/30) harbored HPV integration sites, similar to previously reported percentages \[[@R10], [@R29]\], indicating the presence of a large number of integrated viral genomes in HPV16-positive cervical carcinomas. Moreover, 68% (13/19) of the HPV16 DNA-positive carcinomas were found to harbor more than one DNA junctions per sample. This high percentage of multiple HPV16 integration sites exceeds 15\~20% reported in previous studies using DIPS- PCR and RS-PCR methods \[[@R22], [@R30], [@R31]\], and also exceeds 49% reported in a recent study using TEN16 (Tagging, Enrichment, and Next-generation sequencing of HPV16) assay \[[@R10]\], indicating the more effective performance of HPV capture combined with sequencing adopted in this study for HPV DNA integration site analysis.

It is worthy to note that our data, obtained from 101 validated HPV16 integration sites including 2 integration sites from SiHa cell line, indicated that all the regions of HPV genome can be targeted for the linkage to cellular sequences, even E6 and E7. Doubt arises on the feasibility of the widely used E2:E6/E7 ratio by real-time PCR amplification to determine the physical status of HPV infection, which is based on the assumption that the viral E2 gene is frequently disrupted upon HPV integration, and the HPV E6 and E7 open reading frames are almost always retained, whereas other portions of the HPV genome may be deleted \[[@R32]\]. In contrast, the breakpoints of HeLa and 3 other HPV18-positive cervical cancer cases observed to occur at viral E1, E2, L1 and LCR region have been reported \[[@R15], [@R33]\].

Of the 4 HPV18 DNA-positive cervical carcinomas including HeLa, 100% (4/4) harbored HPV integration sites. This percentage conforms to the estimation of 100% of HPV18-positive cervical carcinomas harboring integrated viral DNA by Southern analysis \[[@R33]\]. The high integration frequency of HPV18 may be related to its greater transforming efficiency *in vitro* and its reported clinical association with more aggressive cervical cancers \[[@R34]\].

PCR and Sanger sequencing were used to verify the HPV integration breakpoints based on one or more discordant paired-end reads. Although the low validation rate for one to three discordant paired-end reads may arise from technical error or integration occurred in a small subset of cancer cells, practically, the criterion using more than three discordant read pairs can cover most breakpoints identified (85/117). It should be noted that no explanation could sufficiently capture the failure of the remaining 16.7% of integration sites for validation based on more than three discordant reads, such as the number of discordant paired-end reads, and the proportion of repetitive sequence in the human genome. Additional research is warranted to reduce the false positive rate.

Viral integration within fragile sites has previously been reported in several studies \[[@R22], [@R35]\]. Fragile sites are genomic regions prone to chromosome breaks that facilitate foreign DNA integration. Of the 117 integration loci identified, 69 were located in or close to a fragile site. It is note that the clustered integration sites on 6p24.3, 8q24.21, 13q22.1, and 20p12.1 were located within 1.8, 1.8, 0.8, and 3 Mb, respectively, of an adjacent fragile site, and that the clusters on 9p22.3, 11p15.4, 20q11.22, and 20q13.2 were located \>5 Mb distant to any known fragile site. Thus, it is tempting to speculate that unknown fragile sites may be identified based on the HPV integration hotspots.

In total, 55 (47%) of the 117 confirmed HPV integration sites were located within cellular genes, most frequently in intronic regions. Moreover, several cellular genes existed in two or more unique HPV integration sites in the current study, including CACNG7, CAPG, HDAC4, TP63, CAGE1, PVT1, MACROD2, and NFIB. HPV integration into an intron will probably disturb expression of the targeted cellular gene. However, only few examples exist, because a direct link between HPV integration and gene alteration must be verified by functional data. TP63, a member of the p53 protein family, acts as a tumor suppressor protein and aberrant expression was noted for several cancer entities including cervical cancer \[[@R36], [@R37]\], supporting the assumption that insertional mutagenesis of cellular genes by HPV integration contributes to cervical carcinogenesis.

In our data, overlapping was the most prevalent pattern accounting for 67% of the 117 validated viral-cellular sequences. A significant enrichment of overlapping nucleotides shared between the human genome and HPV genome at integration breakpoints was observed, indicating that it may play a vital role in the HPV integration process.

Additionally, we observed that the prevalence of HPV DNA in 17 patients who had been treated with radiotherapy and chemotherapy before surgery was lower than that in the group of 30 patients without the pre-operative procedures, but no statistically significant difference was found. While considering the status of HPV integration, we found that 82.4% showed negative for HPV or an absence of HPV integration sites in 17 patients with cervical cancer who had received pre-operative radiotherapy and chemotherapy. These results might indicate that radiotherapy and chemotherapy before surgery had some impact on HPV in cervical carcinoma, especially on HPV integration. A plausible explanation for the decrease of HPV integration is that these cells have been more effectively cleared by treatment. Additionally, we found that all the cervical cancer cases harboring more than four HPV16 integration sites showed clinical features and diagnosis of stage III carcinoma, indicating that the complexity of HPV integration might be associated with advanced cervical cancers.

Taken together, the method of HPV capture combined with sequencing allow a better analysis of multiple HPV subtypes at the same time and to identify the precise nucleotide sequences at the viral-cellular junctions as well as the affected cellular genes. The high number of 117 validated unique HPV integration sites deduced in the study demonstrates the effective performance of this strategy at single-nucleotide resolution. HPV integration is a special pattern of cancer mutation, which has the well-established potential to affect the cellular genes involved in cancer carcinogenesis. Therefore, identification of HPV integration in cervical cancers can provide new insight into the understanding of the cancer genome projects and its role in the pathogenesis of cervical carcinoma. Furthermore, because of the intrinsic random distribution of HPV integration sites, the efficient determination of HPV integration sites would allow them to be served as individualized markers in cervical cancer screening and in the follow-up of patients for the early detection of recurrent disease and metastasis in the future.

MATERIALS AND METHODS {#s4}
=====================

Sample collection and cell lines {#s4_1}
--------------------------------

A total of 47 fresh tissue specimens were collected from patients with cervical cancers who had undergone surgeries at Anyang Cancer Hospital, Henan province, China, between 2009 and 2010. Median age of these patients was 51 years with range 29 to 81 years. Among whom 42 had squamous cell carcinoma, 3 had adenocarcinoma and 2 adenosquamous carcinoma. The HPV16- and HPV18-positive human cervical carcinoma cell lines SiHa and HeLa with defined integration sites served as positive control. SiHa and HeLa cell lines had been obtained from AACT many years ago, and were often used for research purposes. Before undergoing experimentation in this study, these two cell lines had been identified using a PCR-based short tandem repeat (STR) genotyping method.

Individual informed consents had been collected from all study participants. This study received ethical approval from the Institutional Review Board of the hospital.

DNA preparation {#s4_2}
---------------

DNA was extracted using DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany) according to the manufacturer\'s protocol. The DNA concentration was determined via a Nano-Drop (NanoDrop Technologies, Wilmington, Delaware USA).

Overall process of HPV capture and sequencing {#s4_3}
---------------------------------------------

### Prepare DNA whole-genomic library {#s4_3_1}

In order to establish the whole genomic library with the targeted gene specifically, a stretch of 3\~5 μg genomic DNA was sheared to about 150 bp fragments by Covaris S2. These fragments were subsequently end blunted, "A" tailed, adaptor ligated and amplified 10 cycles by PCR. Out of which 1 μl of the prepared library samples was quantified using Nanodrop 2000, and 3 μl identified in 2% agarose gel and the final size of the electrophoresis fragment was around 300bp\~500 bp.

Capture targeted gene regions and sequencing {#s4_5}
--------------------------------------------

HPV probes were designed according to full- length genome of 17 HPV types (6, 11, 16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59, 66, 68, 69, and 82) by MyGenostics (MyGenostics, Baltimore, MD, USA). The overall experiment was conducted according to the manufacturer\'s protocol. In brief, the whole-genomic libraries were hybridized with HPV probes (MyGenostics GenCap Technology), adsorbed onto the beads via biotin and streptavidin magnetic beads, and the uncaptured DNA fragments were removed by washing. Then the eluted fragments containing the targeted gene were enriched by 18 cycles of PCR to generate libraries for sequencing. Libraries were quantified and sequenced for paired-end 100bp using the Illumina HiSeq 2000 sequencer (Illumina Inc., San Diego, CA, USA).

Bioinformatics analysis method {#s4_6}
------------------------------

The 100 bp paired-end reads were preceded into bioinformatics analysis. For quality control, we first filtered low quality reads using the Trim Galore program. Then, 3′/5′ adaptors were trimmed using the Cutadapt program implemented in Trim Galore, thereby rendering high quality clean reads, whose quality value exceeds 20 and read length greater than 80 bp. The high quality reads were obtained for subsequent analysis.

Illumina clean reads were mapped to human genome (GRCh37/hg19) and HPV genome of 17 types (6, 11, 16, 18, 31, 33, 35, 39, 45, 52, 56, 58, 59, 66, 68, 69, and 82) using the BWA program. The quality scores were recalibrated and realigned to reference sequences using the GATK software package. For the potential HPV integration sites in the human genome, we aligned the Illumina clean reads to the reference human genome hg19 using the BWA program, and simultaneously performing recalibration and realignment with GATK. The paired-end read, uniquely mapped with one end to a human chromosome and the other to the HPV reference genome, is identified as a discordant read pair. If a specific position has one or more discordant read pairs, it would be considered as a potential HPV integration site and the breakpoints of which were then identified using the BreakDancer program. The integration sites were annotated according to human genome (GRCh37/hg19) from the UCSC database and HPV genome.

The sample was considered HPV DNA positive when the average sequencing depth was more than 10 and more than 50% of the virus genome\'s total length was covered by at least 4x.

The average sequencing depth was calculated based on sequencing tags containing HPV sequences and according to the following formula: Sequencing Depth = Total HPV bases/genome size. Genome size here means the size of the specific HPV genome.

PCR amplification and Sanger sequencing {#s4_7}
---------------------------------------

To validate the potential HPV integration sites, we designed primers to amplify regions of interest by PCR. PCR products were sequenced directly from both directions using conventional Sanger sequencing. If unsuccessful, the integration sites were identified by TA cloning of PCR products and sequencing. All sequences of the fusion genes were characterized by the NCBI human mega Blast database alignment tool and the UCSC Blat database.

Statistical analysis {#s4_8}
--------------------

Fisher\'s exact test was used for statistical analysis in the present study. *P*-value of less than 0.05 was considered as statistically significant. All the *P*-values presented are two-sided.

SUPPLEMENTARY MATERIALS TABLES AND FIGURES {#s5}
==========================================
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